Beta Bionics shares fall 7.1% after public offering pricing

  • Beta Bionics reported pricing for a public offering of common stock and pre-funded warrants.
  • Beta Bionics shares fell 7.1% to $17.87 in pre-market trading.
  • Horizon Quantum clarified its issued and outstanding equity and Business Combination lock-up agreements remained effective.

U.S. stock futures moved higher Wednesday morning, with Nasdaq 100 futures gaining around 100 points, while several individual shares declined in pre-market trading. Beta Bionics Inc. fell 7.1% to $17.87 after reporting the pricing of a public offering of common stock and pre-funded warrants (warrants whose exercise price is paid upfront). Akso Health Group, J.B. Hunt Transport Services, Lexicon Pharmaceuticals, Cinemark Holdings, Braskem, Ethos Technologies, Horizon Quantum Holdings, CURRENC Group, Resolution Minerals and Horizon Technology Finance also traded lower. Horizon Quantum clarified details about its issued and outstanding common equity and said all lock-up agreements tied to the Business Combination remained in effect. Horizon Technology Finance fell after declining more than 4% on Tuesday.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.